What is the DirectHit™ Test Panel for Breast Cancer (Drug Response Indicator Test)?
The DirectHit Test Panel for Breast Cancer can help doctors determine the best drug treatment regimen for women diagnosed with breast cancer. DirectHit provides information about the tumor that may be used in addition to the standard determinations to prescribe the most effective anticancer drug treatment.
How does the DirectHit DRIT work?
DirectHit examines the amount of certain proteins in a woman’s tumor. These proteins are related to how particular drugs work. After testing is complete, a report is sent to the patient’s physician detailing the protein levels and making a treatment recommendation for several commonly used anticancer drugs.
Which patients may use DirectHit?
DirectHit is performed on preserved tumor tissue removed during original cancer surgery. All women who have experienced surgery for the removal of a breast tumor are eligible for this test. However, if you have received extensive drug treatment since your surgery, DirectHit may not be recommended.
Who may order DirectHit?
Only your physician or oncologist may order the DirectHit Test Panel for Breast Cancer. If you feel that DirectHit is appropriate for you, please contact your health care professional.
Where is DirectHit performed?
The DirectHit Test Panel for Breast Cancer is performed in CCC Diagnostics’ clinical laboratory, located in Baltimore, MD. CCC Diagnostics is licensed by the State of Maryland and registered with CMS as administered by CLIA.
Will my insurance or Medicare cover it?
CCC Diagnostics participates in many national and local health plans. For all contract billing questions, please contact Account Resolutions, LLC at (800) 799-5916.
How long does it take to get the test results?
It typically takes no more than 6 working days from the time the sample is scheduled for testing to receive DirectHit results. Results will be sent to your physician or oncologist.
Are other tests being developed?
Yes, clinical trials are currently being conducted to evaluate the DirectHit technology for use in gastrointestinal cancer patients. Early results indicate a high level of predictive accuracy.
Where can I go for more information?
In addition to the information available on this website, patients can contact:
Scott Deamond Phone – 410-633-4885 x1071 e-mail – Scott@CCCdiag.com